Caris Life Sciences Stock

carislifesciences.comHealthcareFounded: 2008Funding to Date: $465MM

Operator of a biotechnology company specializing in cancer treatment agents. The company is a provider of molecular science focused on fulfilling the promise of precision medicine and facilitating a deeper understanding of cancer biology and other complex diseases through a suite of molecular profiling offerings assess DNA, RNA and proteins that reveal the molecular blueprint, enabling physicians and cancer patients to make more precise and personalized treatment decisions.

Register for Details

For more details on financing and valuation for Caris Life Sciences, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Caris Life Sciences.

Register Today

Team

Management Team

David Halbert
Co-Founder, Chairman and Chief Executive Officer
Ginger Appleberry JD
Chief Compliance Officer & Associate General Counsel
Brian Lamon Ph.D
Chief Business Officer & Head of BioPharma Business Development
Thomas Parker
Chief Financial Officer and Senior Vice President
Ronald Merlino
Senior Vice President & Chief Information Officer
Jim Abraham
Chief Data Officer & Senior Vice President
David Spetzler Ph.D
President & Chief Scientific Officer
Stephanie Thomas
Chief of Staff, Executive Vice President & Office of the CEO

Board Members

Brian Brille JD
Caris Life Sciences
George Poste Ph.D
Laurie Johansen JD
Caris Life Sciences
Danny Phillips
Jon Halbert
Caris Life Sciences
Peter Castleman
J.H. Whitney Capital Partners
David Halbert
Caris Life Sciences
Jonathan Knowles Ph.D
Caris Life Sciences
Vijay Mohan
Sixth Street Specialty Lending

Other companies like Caris Life Sciences in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$885.01MM

News

News items for the week of April 11, 2022.
News items for the week of Oct. 25, 2021.
The pharma firm will use Caris' comprehensive sequencing services, including its liquid biopsy assay, to advance development of targeted and immuno-oncology drugs.